---
schema_version: "secwatch.filing_event.v1"
accession: "0001651308-22-000208"
form_type: "8-K"
ticker: "ONC"
cik: "0001651308"
company_name: "BeOne Medicines Ltd."
filed_at: "2022-11-09T23:59:59+00:00"
generated_at: "2026-06-22T01:26:41.033896+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# BeiGene Q3 product revenue up 82% to $349.5M; BRUKINSA sales +136%; net loss widens

## Summary
- Product revenue $349.5M (+82% YoY); BRUKINSA global sales $155.5M (+136%), U.S. $108.1M (+221%).
- Net loss $557.6M ($0.41/share) vs $438.1M loss prior year; includes $125.6M FX losses.
- Cash $5.1B (down from $6.6B); cash used in operations $561.9M.
- BRUKINSA achieved superior PFS vs ibrutinib in ALPINE final analysis; EC approved MZL; CHMP positive for CLL.
- Tislelizumab China sales $128.2M (+67%); HCC trial met OS endpoint vs sorafenib.

## SEC filing metadata
- accession: 0001651308-22-000208
- form_type: 8-K
- ticker: ONC
- cik: 0001651308
- company_name: BeOne Medicines Ltd.
- filed_at: 2022-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1651308/000165130822000208/0001651308-22-000208-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1651308/000165130822000208/bgne-20221109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001651308-22-000208
- JSON: https://secwatch.observer/filing/0001651308-22-000208.json
- Plain text: https://secwatch.observer/filing/0001651308-22-000208.txt

## Key facts
- Earnings Releases
  BeOne Medicines Ltd. reported the three months ended September 30, 2022 results: revenue $387.6 million, net income net loss of $557.6 million.
  - Period: the three months ended September 30, 2022
  - Revenue: $387.6 million
  - Net income: net loss of $557.6 million
  - Result: reported results
  source text: into the U.S. dollar negatively impacted ending cash by $62.7 million in the three months ended September 30, 2022. Revenue for the three months ended September 30, 2022 was $387.6 million, compared to $206.4 million in the same period of 2021. • Product revenue totaled $349.5 million for the three months ended September 30, 2022, compared to $192.5 million in the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1651308/000165130822000208/0001651308-22-000208-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.